BridgeMD
Compares treatment options for Chronic Obstructive Pulmonary Disease
Official title Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients
ClinicalTrials.gov ID: NCT06377410
What this study is testing
What is Syrup Prospan?
Syrup Prospan is an investigational medicine, given as an once-daily, being studied as a potential treatment for chronic obstructive pulmonary disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD) affects more than 300 million people worldwide. These patients suffer from 0.5-3.5 exacerbations per year on average.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Participants with documented post bronchodilator FEV1/FVC \< 70 or \<LLN
- Age 40 years and above
- Able to perform spirometry
- Participant with Stable COPD based on GOLD 2023 strategy
You likely can't join if
- Diagnosis of other chronic lung diseases: Asthma, Asthma-COPD Overlap, Interstitial Lung Disease, Bronchiectasis, Lung Cancer
- Participants with contraindication for spirometry: recent cardiac complications, major surgery, severe advanced respiratory disease, or those with...
- Hypersensitivity to acetylcysteine or any component of the formulation
- Hypersensitivity to dry powder ivy extract
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation...
- Participant on pre-existing regular mucolytics (at least 1 month prior)
See the full eligibility criteria
- Participants with documented post bronchodilator FEV1/FVC \< 70 or \<LLN
- Age 40 years and above
- Able to perform spirometry
- Participant with Stable COPD based on GOLD 2023 strategy
- Diagnosis of other chronic lung diseases: Asthma, Asthma-COPD Overlap, Interstitial Lung Disease, Bronchiectasis, Lung Cancer
- Participants with contraindication for spirometry: recent cardiac complications, major surgery, severe advanced respiratory disease, or those with cognitively or neurologically impairment
- Hypersensitivity to acetylcysteine or any component of the formulation
- Hypersensitivity to dry powder ivy extract
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human Chorionic Gonadotropin) laboratory...
- Participant on pre-existing regular mucolytics (at least 1 month prior)
- Illiterate participants
The study team makes the final eligibility decision.
Where it's taking place
- Cheras, Kuala Lumpur, Malaysia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cheras, Kuala Lumpur, Malaysia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.